Three More Biotechs Price Their Nasdaq IPOs

Why It Matters

The combined $550‑$600 million capital raise underscores a resurgence of funding for biotech companies with advanced pipelines, potentially accelerating development of therapies for Crohn’s disease, glaucoma, and hair loss. This momentum may broaden Nasdaq’s biotech representation and attract further institutional investment.

Key Takeaways

• AgomAb aims to raise $200M, valuing at $875M
• SpyGlass targets $150M raise, valuation around $550M
• Veradermics seeks $200M, valuation over $530M
• All three price shares $14-$17, mid‑stage pipelines
• Biotech IPO sentiment improves after 2024‑25 slump

Pulse Analysis

After a pronounced dip in biotech listings during 2024 and early 2025, the Nasdaq has seen a modest revival, highlighted by four companies pricing IPOs this week. Investors appear more willing to back firms that have progressed beyond early‑stage research, especially those with clear pathways to commercial products. The aggregate raise of roughly $550 million reflects both renewed risk appetite and the sector’s search for fresh capital to fund late‑stage trials. This uptick also signals that the market is rewarding differentiated therapeutic platforms over speculative early‑stage concepts.

AgomAb Therapeutics, based in Antwerp, is betting on two ALK5 inhibitors—AGMB‑129 for fibrostenosing Crohn’s disease and AGMB‑447 for idiopathic pulmonary fibrosis—positioning itself in high‑unmet‑need gastrointestinal and lung markets. SpyGlass Pharma brings a drug‑eluting intraocular lens, BIM‑IOL, into phase‑3 trials for glaucoma, a chronic condition affecting millions and ripe for device‑based delivery solutions. Veradermics targets the sizable hair‑loss market with an oral, extended‑release minoxidil formulation, VDPHL01, which could capture patients dissatisfied with topical applications. Each pipeline addresses sizable patient populations, offering clear revenue pathways that justify the $14‑$17 per‑share pricing.

The combined valuations—ranging from $530 million to $875 million—place these firms among the most promising mid‑cap biotech entrants on Nasdaq, potentially attracting both strategic partners and long‑term institutional investors. Should the IPO proceeds fund successful phase‑3 readouts, the companies could unlock sizable market share and set a precedent for similar specialty‑focused biotech offerings. Analysts will watch post‑pricing performance closely, as sustained demand could cement a broader resurgence of biotech capital and encourage other late‑stage developers to pursue public listings sooner rather than later.